CurrentPremera BluecrossPolicy 7.01.84

Middle ear hearing aids (semi‑ and fully‑implantable)

Policy governing coverage and investigational status of semi‑implantable and fully implantable middle ear hearing aids for members and providers under Premera Bluecross.

Policy Summary

PayerPremera Bluecross

PolicyMiddle ear hearing aids (semi‑ and fully‑implantable)

Policy CodePolicy 7.01.84

Change TypeNo material change

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization when required and document device‑specific selection criteria, imaging, and a trial of appropriately fitted external hearing aids when applicable.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2FDA‑approved semi‑implantable devices

1FDA‑approved fully implantable device

36 moWA mandate interval (per ear)

≥18 yrsAge group

2003–2026Policy history span

Coverage Determinations and Rationale

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

General stance: investigational / insufficient evidence

Covered only when device is not investigational and meets device‑specific indications; otherwise investigational and not covered.

General coverage logic: Semi‑implantable and fully implantable middle ear hearing aids are considered investigational due to insufficient evidence to determine improvement in net health outcomes compared with external acoustic hearing aids; coverage requires demonstration of clinically significant improvement over external aids and adherence to FDA indications.

Policy states investigational for middle ear hearing aids except where evidence and FDA approval support use; overall evidence insufficient.

Indications and payer/regulatory context

Coverage references and clinical indications from regulatory and Medicare sources

General indication for implantable middle ear devices: Device use is indicated for adults (18+) with moderate to severe sensorineural hearing loss who desire an alternative to conventional hearing aids and who cannot benefit from or cannot use conventional hearing aids.

Based on FDA labeling for Vibrant Soundbridge/Direct/Maxum and Esteem device approvals.

Regulatory and payer considerations: Medicare excludes routine hearing aids but will pay for devices that replace middle ear, cochlear, or auditory nerve function when hearing aids are medically inappropriate or cannot be utilized; institutional coding updates (CPT 0951T–0955T) were added to align with criteria.

No Medicare national coverage determination for semi‑ or fully implantable devices; CPT codes 0951T–0955T added 07/01/25.

Semi‑implantable and fully implantable middle ear hearing aids are designated investigational in this policy unless specific device indications and evidence demonstrate clinically significant benefit over conventional external acoustic hearing aids. The policy notes that available evidence — single‑arm interventional studies, systematic reviews, and observational series — suggests some hearing improvement for sensorineural hearing loss but is limited by small sample sizes and follow‑up duration; therefore overall evidence is insufficient to determine improvement in net health outcomes for these devices. (See device‑specific FDA approvals and clinical trial data when assessing coverage exceptions.)

Medicare policy excludes routine hearing aids from coverage; however, Medicare will consider payment for devices that replace the function of the middle ear, cochlea, or auditory nerve as prosthetic devices when hearing aids are medically inappropriate or cannot be used (for example, due to congenital malformations, chronic disease, severe sensorineural hearing loss, or prior surgery). The Medicare Benefit Policy Manual does not specifically list semi‑ or fully implantable middle ear hearing aids as prosthetic devices.

Clinical studies of semi‑ and fully‑implantable middle ear hearing aids have enrolled relatively few patients and generally report a median follow‑up of 5 years; this limited sample size and short duration of follow‑up restricts confidence in long‑term safety and effectiveness. Consequently, the evidence base does not adequately establish whether the surgical risks and device performance provide sustained, net health benefit compared with external acoustic hearing aids.

Historically, the policy has treated semi‑implantable and fully implantable middle ear hearing aids as investigational; prior updates and annual reviews through 2019 recorded no change to the investigational policy statements. The current document retains that investigational stance except where specific device approvals and supporting evidence meet the policy’s coverage requirements.

Procedure and Billing Codes

CPT (Totally implantable middle ear hearing implant series)CPT

0951T	Totally implantable active middle ear hearing implant; initial placement, including mastoidectomy, placement of and attachment to sound processor (new code effective 07/01/25).
0952T	Totally implantable active middle ear hearing implant; revision or replacement, with mastoidectomy and replacement of sound processor (new code effective 07/01/25).
0953T	Totally implantable active middle ear hearing implant; revision or replacement, without mastoidectomy and replacement of sound processor (new code effective 07/01/25).
0954T	Totally implantable active middle ear hearing implant; replacement of sound processor only, with attachment to existing transducers (new code effective 07/01/25).
0955T	Totally implantable active middle ear hearing implant; removal, including removal of sound processor and all implant components (new code effective 07/01/25).

HCPCSHCPCS

S2230	Implantation of magnetic component of semi-implantable hearing device on ossicles in middle ear.
V5095	Semi-implantable middle ear hearing prosthesis

Added CPT Codes Q3 updateCPT

0951T	new implantable hearing device code (as added)
0952T	new implantable hearing device code (as added)
0953T	new implantable hearing device code (as added)
0954T	new implantable hearing device code (as added)
0955T	new implantable hearing device code (as added)

Pure-tone average / word recognition thresholds

Vibrant Soundbridge word recognitionMinimum recorded-word recognition score ≥50% per device package insert

Esteem unaided speech discriminationUnaided speech discrimination (word recognition) ≥40% as stated in Esteem indications

Pure‑tone average rangesEsteem: moderate (40–70 dB) to severe (71–90 dB) sensorineural hearing loss by pure‑tone average; Vibrant Soundbridge: device-specific pure‑tone air‑conduction thresholds as shown in package insert Table 1

Authorization, Documentation, and Clinical Preconditions

Prior Authorization

Prior Authorization / Benefit Verification

A health carrier may require prior authorization or adopt other utilization controls when approving coverage for medically necessary hearing instruments. Confirm member-specific benefits and any prior authorization requirements before scheduling services.

Prior authorization may be required per member contract and applicable state mandates.

Denial Risk

Investigational / Denial Risk

Semi‑implantable and fully implantable middle ear hearing aids have limited evidence and specific FDA indications. If the device or indication is considered investigational under this policy, claims may be denied. Document clinical rationale thoroughly when requesting coverage for devices that are not standard external acoustic hearing aids.

Investigational stance may trigger denial — ensure clinical justification and evidence are provided.

Documentation Required

Documentation Requirements

Document device selection criteria, pertinent imaging, and prior conservative treatments in the medical record and on authorization requests. Relevant documentation includes audiometric thresholds, word recognition scores, otologic exam findings, CT imaging when applicable, and trials of appropriately fitted hearing aids.

Pure‑tone audiometry and word recognition scores (per device labeling)
High‑resolution CT imaging to demonstrate adequate anatomy/space when required
Operative and preoperative evaluations and notes

Note

Follow FDA Labeling

Follow FDA‑approved labeling and indications for each implantable device when determining eligibility and preparing authorization requests. Note patient age restrictions, audiometric thresholds, speech discrimination requirements, and device‑specific prerequisites noted in approved labeling.

Vibrant Soundbridge, Maxum System, and Esteem labeling — adhere to age and audiometric criteria

Step Therapy

Conservative Step: Trial of Hearing Aids

A conservative management step is expected: individuals should have a documented trial (minimum 30 days unless otherwise specified by device labeling) of appropriately fitted external acoustic hearing aids prior to consideration of implantable middle ear devices, unless hearing aids are contraindicated or not tolerated.

Minimum 30 days experience with appropriately fitted hearing aids (device labeling and policy)
Document reason external hearing aids are inappropriate if no trial was possible

Note

Use of Implants When Hearing Aids Inappropriate

Implantable middle ear devices are intended for use when external acoustic hearing aids are inappropriate or cannot be utilized. When implants are considered, document why hearing aids are inadequate (anatomic issues, sound quality, intolerance) and reference device selection criteria and imaging as applicable.

Use of implants when hearing aids are inappropriate — document specific contraindications or prior failures of hearing aids

Device Definitions and Examples

Semi‑implantable middle ear hearing aid — definition and components

DefinitionSemi‑implantable middle ear hearing aid: device with implanted magnetic component on the ossicles plus an external receiver and sound processor that transduces electromagnetic energy to vibrate middle ear bones

Typical componentsImplanted magnetic component on ossicles; subcutaneous receiver implanted behind the ear or receiver in ear canal; external sound processor worn on scalp or over external ear

FDA‑approved examplesVibrant Soundbridge (MED‑EL) and Maxum System (rebranded Soundtec) are FDA‑approved semi‑implantable devices for adults ≥18 years

Fully implantable middle ear hearing aid — definition and components

DefinitionFully implantable middle ear hearing aid: device implanted entirely (sensor, sound processor, and driver) that uses piezoelectric transduction to deliver signals to the ossicles

Typical componentsImplanted sensor (placed at incus), implanted sound processor, and implanted driver attached to the stapes/ossicular chain; no external processor required for basic function

FDA‑approved exampleEsteem Implantable Hearing System (Envoy Medical) approved for adults ≥18 years with stable bilateral sensorineural hearing loss

Vibrant Soundbridge / Direct/Maxum — device‑specific note

Device family and indicationVibrant Soundbridge (MED‑EL) is a semi‑implantable active middle ear device indicated for adults ≥18 years with moderate‑to‑severe sensorineural hearing loss who desire an alternative to acoustic hearing aids

Selection criteria (examples)Package insert specifies pure‑tone air‑conduction thresholds (see Table 1), normal middle ear anatomy, and word recognition score ≥50% using recorded material

Implant/processor configurationSoundbridge has a subcutaneous implanted receiver and an external processor worn on the scalp held by a magnet; Maxum variant places processor in ear canal with external unit over ear

Esteem — fully implantable device note

Device noteEsteem is a fully implantable middle ear hearing system intended for adults ≥18 years with stable bilateral sensorineural hearing loss

Audiometric thresholdsIndicated for moderate (40–70 dB) to severe (71–90 dB) sensorineural hearing loss defined by pure‑tone average per device labeling

Speech discrimination requirementUnaided speech discrimination (speech discrimination test score) ≥40% as specified in Esteem labeling

OpenPayer

Middle ear hearing aids (semi‑ and fully‑implantable)

Coverage Determinations and Rationale

Procedure and Billing Codes

Authorization, Documentation, and Clinical Preconditions

Clinical and Device Background

Device Definitions and Examples

Policy Revision Timeline